
Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

Evan Stein, MD, PhD, is the COO and CSO of LIB Therapeutics.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.